You are here

Article Text

Article menu
Download PDFPDF
DTB Select
MHRA drug safety update: hydrochlorothiazide and non-melanoma skin cancer

https://doi.org/10.1136/dtb.2019.000023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Medicines and Healthcare products Regulatory Agency. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use. Drug Safety Update 2018; 12(4): 2.

    Key learning points

    • The Medicines and Healthcare products Regulatory Agency has reported a cumulative, dose-dependent risk of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) in people taking hydrochlorothiazide.

    • It was estimated that around 9 in 100 SCC cases, 11 in 100 SCC lip cancer cases and fewer than 1 in 100 BCC cases diagnosed during the study periods may be attributed to hydrochlorothiazide use.

    Patients taking hydrochlorothiazide-containing products should be informed of the risk of non-melanoma skin cancer and should regularly check for, and report, any new or changed skin lesions or moles.1

    Overview

    The Medicines and Healthcare products …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.